Neurotoxicosis in 4 Cats Receiving Ronidazole

Terri W. Rosado, Andrew Specht, and Stanley L. Marks

Trypanosoma foetus is a protozoan that can cause chronic large-bowel diarrhea in cats.1 Ronidazole, a nitroimidazole, has been shown to effectively treat T. foetus in cats at doses of 30 to 50 mg/kg body weight twice daily for 14 days.2 To our knowledge, adverse effects in cats have not been reported. This case series describes neurologic abnormalities suspected to be secondary to ronidazole administration in 4 cats.

Case 1 is a 2.5-year-old male castrated Domestic Shorthair that was presented with a chief complaint of chronic, intermittent, mucohemorrhagic diarrhea of 1.5 years’ duration. The owner was unable to comment about the frequency or the urgency of defecation.

The cat, when 6 weeks of age, was adopted by the owner from a rescue organization and had been housed strictly indoors since then. He resided with 5 other cats, all of whom tested negative for feline leukemia virus (FeLV) and feline immunodeficiency virus (FIV) and had no history of diarrhea. The only medical problems among the cats were occasional upper respiratory tract infections.

Serum biochemistry panel, CBC, and T4; a blood smear to scan for Mycoplasma hemofelis; and (ELISA) for FeLV antigen and FIV antibody (FeLV/FIV test), performed by the referring veterinarian (rDVM) were unremarkable. Coronavirus 7B antibody titers were 1:80, 1:160, and 1:80 on 3 sequential serum samples in an 8-week period.

Initial physical examination (PE) revealed a bright, alert, responsive, and well-hydrated cat. He weighed 4.7 kg, with a body condition score (BCS) of 7 of 9. Rectal temperature was 102.9°F, and a small amount of frank blood was observed on the thermometer. The patient had a mild serous ocular and nasal discharge, as well as gingivitis, faucitis, and halitosis. The remainder of his PE was unremarkable.

Serum chemistry profile, CBC, urinalysis, abdominal ultrasound, and FeLV/FIV test were all unremarkable. Fecal flotation and direct wet preparation were negative for intestinal parasite ova and motile protozoa; Giardia ELISA was negative; stained direct preparations were unremarkable; and fecal cultures for Salmonella, Yersinia, and Campylobacter were negative. A rectal scrape revealed neutrophilic inflammation, with occasional cocci, diplococci, and a few sporulating bacteria consistent with Clostridium sp. A second fecal wet smear was positive for flagellated protozoa. Culture for Trypanosoma foetus was positive, and the patient was prescribed ronidazole at a dose of 54 mg/kg PO q12h for 14 days.

Five days after starting ronidazole, the owner reported that the cat had normal stools, lethargy, a blank stare, and appeared to be in “slow motion.” Neurologic evaluation of the cat was declined, and the ronidazole was continued for an additional 3 days. These clinical signs progressed, and the cat also developed an unsteady gait, pelvic-limb weakness, and trembling. Ronidazole therapy was discontinued, and the cat remained stable over several days, with gradual improvement. The patient was presented 7 days after discontinuation of ronidazole, and physical examination revealed a crouching, wide-based stance and mild ataxia in the pelvic limbs. The rest of the physical examination was unremarkable. The cat had complete resolution of its neurologic signs 1 month after discontinuation of ronidazole, and physical examination was unremarkable.

The hematochezia recurred several days after discontinuing the ronidazole. Direct wet preparation of feces for motile protozoa and culture for T. foetus were negative; however, the owner elected to re-treat with ronidazole at a lower dose (30 mg/kg PO q12h). The hematochezia resolved quickly, but, 12 days later, the owner reported that the cat had been unsteady, stumbling, and “spacey” for several days and that she had been giving him only 1 dose daily during this period. Neurologic signs resolved over a period of weeks after discontinuation of ronidazole. The patient was returned for reevaluation approximately 6 weeks after discontinuing the second course of ronidazole, and the PE was unremarkable. Culture of fresh feces was negative for T. foetus.

Case 2 is a 5-year-old female spayed Persian who was examined because of chronic mucohemorrhagic diarrhea since the cat was acquired from a breeder at 4 months of age. The diarrhea episodes initially occurred 6 to 8 times daily, and the cat was fecally incontinent. Routine deworming by the rDVM with pyrantel pamoate and empiric antimicrobial administration with metronidazole had no effect on the diarrhea. Dietary trials with Royal Canin Innovative Veterinary Diet Green Peas and Venison, Hill’s Prescription diet w/d, and Nestle Purina OM also had no effect on the diarrhea. The rDVM obtained multiple full-thickness biopsy specimens from the small and large intestines, which were characterized by mild lymphoplasmacytic inflammation. The cat was
Salmonella T. foetus has been recognized as a cause of chronic k. spp., and –associated diarrhea was Campylobacter T. foetus Crypto- were unremarkable. An abdominal were T. Many antibiotics and antiprotozoal was positive for Clostridium difficile l performed 3 days after initi- T foetus The PCR reaction amplified the 5.8S- and was performed i e via PCR. and empirically Clostridium perfringens 1,4,5 e were negative. enter- T foetus direct fluorescent antibody[58x49]a painful anus. The rest of the PE was unremarkable. would not tolerate a rectal thermometer because of temperature could not be determined, because the cat weighed 2.3 kg and had a BCS of 3 of 9. The remainder of the PE was unremarkable.

Serum biochemistry profile, CBC, urinalysis, and FeLV/FIV test were unremarkable. An abdominal ultrasound revealed mild enlargement of the mesenteric and sublumbar lymph nodes. However, there was no evidence of intestinal-wall thickening. Fecal direct wet preparation and centrifugation fecal flotation were negative. A fecal culture for T. foetus was positive for trophozoites and confirmed via PCR by using species-specific primers.3,4 The PCR reaction amplified the 5.8S-ribosomal ribonucleic acid (rRNA) gene unit of T. foetus and product identity was confirmed by sequencing.

Ronidazole was administered at a dosage of 40 mg/kg PO q12h for 10 days. The cat’s fecal consistency improved within 3 days. A repeat fecal culture for T. foetus on day 3 after initiation of ronidazole was negative. The owner reported no apparent problems with the cat 7 days after initiation of drug therapy, but the cat’s appetite was notably decreased on day 8, and the cat became anorectic on day 9. In addition, the cat became extremely agitated and lethargic and was noted to have facial tremors and trembling of all extremities. Despite these signs, the owner completed the prescribed course of ronidazole therapy. The cat became progressively more unstable in the thoracic and pelvic limbs over the ensuing 48 hours until it became very weak and could no longer jump on the bed or walk up stairs. The cat remained inappetent for 7 more days, and the neurologic signs resolved over 14 days. Fecal culture for Trichomonas was performed 4 days after completion of ronidazole therapy and was negative. In addition, the cat continued to have normal formed feces 3 months after completion of ronidazole administration.

Case 3 is an 18-month-old male neutered Abyssinian who was examined because of chronic intermittent mucohemorrhagic diarrhea of 12 months’ duration. The cat was obtained from a breeder when the cat was 6 months of age, and the owner witnessed a bout of hematochezia within 2 days of purchase. The cat tested negative for FeLV and FIV, and was subsequently dewormed with praziquantel and pyrantel embonate and empirically treated with metronidazole and sulfadimethoxine, with no effect. The cat maintained an excellent appetite, despite the diarrhea, and had no history of vomiting.

Physical examination revealed a bright, alert, and responsive cat who weighed 4.6 kg (BCS, 5/9). The cat’s temperature could not be determined, because the cat would not tolerate a rectal thermometer because of a painful anus. The rest of the PE was unremarkable.

Serum biochemistry profile, CBC, and abdominal ultrasound were unremarkable. Direct wet preparation, centrifugation fecal flotation, fecal culture for Clostridium difficile, Campylobacter spp., and Salmonella spp., ELISA for detection of Clostridium perfringens enterotoxin and Clostridium difficile toxin A and Cryptosporidium/Giardia direct fluorescent antibody test were negative; however, fecal culture was positive for trophozoites, confirmed to be T. foetus via PCR.

Ronidazole was administered at a dosage of 40 mg/kg q12h for 10 days. The cat was hospitalized for the first 3 days of ronidazole administration for close monitoring, and no abnormalities were detected during daily PEs. The cat did not defecate for 3 days after ronidazole administration. The cat continued to do well at home after discharge, and the owner reported that the cat’s fecal consistency had improved dramatically within 5 days of starting ronidazole therapy. However, starting on day 9 of ronidazole administration, several new clinical signs were noted, including agitation, lethargy, anorexia, trembling of extremities, and instability in the thoracic and pelvic limbs. The owner also reported that the cat had become extremely hyperesthetic to external stimuli. The neurologic complications and hyperesthesia progressively resolved over an 8-day period after cessation of the drug. The cat regained its appetite 10 days after stopping the ronidazole, made a complete recovery, and continued to have well-formed stools. Additional fecal cultures performed 3 days after initiating ronidazole therapy and 5 weeks after completion of ronidazole administration were negative.

Case 4 is a 2-year-old male neutered Domestic Medium Hair who was evaluated for persistent tenesmus, hematochezia, fecal incontinence, and extremely malodorous stools since being adopted from a shelter 1 year before presentation.

Physical examination was unremarkable, although the cat was deemed to be overweight (5 kg; BCS, 6/9). Results of a serum chemistry profile and CBC were unremarkable. Repeated centrifugation fecal flotation and Cryptosporidium/Giardia direct fluorescent antibody tests were negative. T. foetus–associated diarrhea was suspected, despite negative fecal culture.

Ronidazole was administered empirically at a dosage of 40 mg/kg PO q12h for 10 days. The cat was hospitalized for the first 3 days of ronidazole administration for close monitoring. The cat became extremely agitated and hyperesthetic after 3 days of ronidazole therapy and was difficult to restrain. The cat was described as a “mellow” animal normally, and the owner was alarmed at the cat’s profound hyperesthesia to touching and any sudden movements by people. The drug was discontinued after an additional 3 days of therapy because of the progressive behavioral changes and lack of any improvement in fecal quality. The cat’s agitation and hyperesthesia resolved over the ensuing 8 days.

T. foetus has been recognized as a cause of chronic diarrhea in cats. Many antibiotics and antiprotozoal agents have been used in an effort to treat T. foetus diarrhea, without consistent success. Ronidazole has
been identified as a treatment for *T. foetus* in cats, when other drugs have been unsuccessful or deemed unsafe. It is a nitroimidazole, similar to metronidazole and is used as a treatment for trichomoniasis in birds. Currently, there is no commercially available pharmaceutical product in the United States, but the chemical is available through Sigma-Aldrich Pharmaceuticals at greater than 99.9% purity, and many pharmacies will compound the drug into capsules. This compound is not approved for use in cats by the Food and Drug Administration.

To the authors’ knowledge, there is no published information about the pharmacokinetics, pharmacodynamics, or adverse effects profile of ronidazole in cats. In other species, ronidazole and its metabolites are excreted in urine and feces. It is readily absorbed from the gastrointestinal tract and biodegraded, and is found in its intact form only in muscle.

The primary mechanism of action of most nitroimidazoles (including ronidazole) is thought to be related to production of nitro anion radicals, leading to destabilization of DNA in hypoxic mammalian cells in vitro. Superoxide radicals, hydrogen peroxide, nitrofurantoin radicals, and semiquinone radicals from catecholamine metabolism of hypoxic mammalian cells secondary to use of 5-nitroimidazoles has been theorized to be because of the formation of free radicals, hydrogen peroxide, nitrofurantoin radicals, and semiquinone radicals from catecholamine reduction of these drugs under aerobic conditions. Other research indicates that the cytotoxic mechanism of nitroimidazoles in anaerobic protozoa also occurs in hypoxic mammalian cells in vitro. Cytotoxicity of aerobic cells does not occur because of the low redox potential of 5-nitroimidazoles.

In the 4 cases described here, ronidazole was used to treat documented or suspected trichomonad infections. Adverse effects attributed to ronidazole in these cats included decreased appetite, altered mentation, trembling, weakness, ataxia, and hyperesthesia. No seizures were observed in any of the cats. Neurologic signs started between 3 to 9 days after initiating ronidazole therapy and lasted between 1 and 4 weeks, gradually diminishing after discontinuation of the medication. Continuation of ronidazole therapy in 3 cases after signs were noted may have affected the duration of signs in these cases. It is also worth noting that in the 3 cases in which trichomonad infections were documented, diarrheea resolved after ronidazole treatment and post-treatment *Trichomonas* cultures were negative.

The dose of ronidazole used to treat the cats in this report was equal to or greater than 60 mg/kg/d in all cases. A recent study of the efficacy of ronidazole for treatment of *T. foetus* infection in cats found that a dose of 20 mg/kg/d (divided) was associated with relapsing infection in all cases, whereas doses of 60 mg/kg/d or 100 mg/kg/d (divided) resulted in clearance of infection for the duration of testing (21–30 weeks). The effective doses of 60–100 mg/kg/d are significantly higher than the doses at which toxic effects were consistently seen in.
other species. It is not possible to determine from these cases whether the toxicity of ronidazole in cats might be dose-dependent as suggested by experimental studies involving dogs and rats. However, additional studies are warranted to determine the efficacy of ronidazole administration at doses between 20 and 60 mg/kg/d.

Based upon clinical signs exhibited by the cats described in this series, it appears likely that adverse effects of ronidazole reported in dogs may also occur in cats. The aim of this report is to alert veterinarians to these potential adverse neurologic effects of ronidazole in cats. Although all cats had complete resolution of their neurologic signs, it may be prudent to discontinue use of ronidazole even if only mild neurologic abnormalities are seen. Clearly, further investigation of ronidazole activity and side effects in felines is necessary. At present, we recommend that the use of ronidazole be limited to confirmed cases of *T. foetus* infection and that owners be educated about the potential adverse effects of this medication.

### Footnotes

* Antech Diagnostics, Atlanta, Ga
* SNAP Combo Test, Idexx Laboratories, Westbrook, ME
* Antech Diagnostics, Atlanta, Ga
* Giardia SNAP ELISA, Idexx Laboratories, Westbrook, ME
* InPouch TM TF, BioMed Diagnostics, White City, OR
* Sigma Chemical Company, St. Louis, MO
* Nemex, Pfizer Animal Health, Exton, PA
* University of California, Davis, School of Veterinary Medicine, CA
* Drontal, Bayer HealthCare LLC, Animal Health Division, Shawnee Mission, KS
* *C. perfringens* enterotoxin test, Techlab Inc, Blacksburg, VA
* Triage Micro *C. difficile* panel Toxin A and common antigen (glutamate dehydrogenase (GD), Biosite Inc, San Diego, CA
* Merilfluor, Meridian Bioscience, Inc, Cincinnati, OH
* Levy MG, Gookin JL, Poore MF, et al. Intestinal trichomonosis in cats: pathology, diagnosis and susceptibility to antiprotozoal drugs. Proceedings of the Joint Meeting of the American Society of Parasitologists and the Society of Protozoologists 2000, San Juan, Puerto Rico, 108 (abstract)

### References

1. Gookin JL, Levy MG, Law JM, et al. Experimental infection of cats with *Trichomonas foetus*. Am J Vet Res 2001;62: 1690–1697.
2. Gookin JL, Copple CN, Papich MG, et al. Efficacy of ronidazole for treatment of feline *Trichomonas foetus* infection. J Vet Inern Med 2006;20:536–543.
3. Felleisen RSJ, Lambelet N, Bachmann P, et al. Detection of *Trichomonas foetus* by PCR and DNA enzyme immunoassay based on rRNA gene unit sequences. J Clin Microbiol 1998;36: 513–519.
4. Gookin JL, Breitschwerdt EB, Levy MG, et al. Diarrhea associated with trichomonosis in cats. J Am Vet Med Assoc 1999;215:1450–1454.
5. Levy MG, Gookin JL, Poore M, et al. *Trichromonas foetus* and not *Pentatrichromonas hominis* is the etiologic agent of feline trichomonal diarrhea. J Parasitol 2003;89:99–104.
6. Gookin JL, Riviere JE, Gilger BC, et al. Acute renal failure in four cats treated with paromomycin. J Am Vet Med Assoc 1999;215:1821–1823.
7. Fransen FF, Lumeij JT. In vitro nitroimidazole resistance of *Trichomonas gallinae* and successful therapy with an increased dosage of ronidazole in racing pigeons (*Columba livia domestica*). J Vet Pharmacol Ther 1992;15:409–415.
8. Rosenbloom C, Trenner NR, Buhs RP. Metabolism of ronidazole. J Agric Food Chem 1972;20:360–371.
9. Wolf FJ, Alvaro R, Steffens JJ, et al. Tissue residues due to ronidazole. J Agric Food Chem 1984;32:771–714.
10. Wolf FJ, Baylis FP, Smith GE, et al. Disposition of ronidazole by swine. I. Radiocarbon content of tissues. J Agric Food Chem 1983;31:559–564.
11. West SB, Wislock PG, Fiorent KM, et al. Drug residue formation from ronidazole. Chem Biol Interact 1982;41:265–279.
12. Moreno SNJ, Mason RP, Muniz RPA, et al. Generation of free radicals from metronidazole and other nitroimidazoles by *Trichomonas foetus*. J Bio Chem 1983;258:4051–4054.
13. Ramakrishna Rao DN, Mason RP. Generation of nitro radical anions of some 5-nitrofurans, 2- and 5-nitroimidazoles by norepinephrine, dopamine, and serotonin. J Biol Chem 1987;262:11731–11736.
14. Edwards DI. Nitroimidazole drugs—action and resistance mechanisms. I. Mechanisms of action. J Antimicrob Chemother 1993;31:9–20.
15. Cerkasovova A, Cerkasov J, Kulda J. Metabolic differences between metronidazole resistant and susceptible strains of *Trichromonas foetus*. Mol Biochem Parasitol 1984;11:105–118.
16. Kulda J. Trichomonads, hydrogenosomes and drug resistance. Int J Parasitol 1999;29:199–212.
17. Toxicological evaluation of certain veterinary drug residues in food. World Health Organization Food Additives Series no. 25, 1990; no. 669, on INCHEM.
18. Olson EJ, Morales SC, McVey AS, et al. Putative metronidazole neurotoxicosis in a cat. Vet Pathol 2005;42:665–669.
19. Caylor KB, Cassimatis MK. Metronidazole neurotoxicosis in two cats. J Am Anim Hosp Assoc 2001;37:258–262.
20. Dow SW, LeCouteur RA, Poss ML, et al. Central nervous system toxicosis associated with metronidazole treatment of dogs: five cases (1984–1987). J Am Vet Med Assoc 1989;195:365–368.
21. Frytak S, Moertel CH, Childs DS. Neurologic toxicity associated with high-dose metronidazole therapy. Ann Intern Med 1978;99:361–362.
22. Ramakrishna Rao DN, Mason RP. Generation of nitro radical anions of some 5-nitrofurans, 2- and 5-nitroimidazoles by norepinephrine, dopamine, and serotonin. J Biol Chem 1987;262:11731–11736.
23. Knox RJ, Knight RC, Edwards DI. Interaction of nitroimidazole drugs with DNA in vitro: structure-activity relationships. Br J Cancer 1981;44:741–745.